Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
FOX04-DRI
A synthetic D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction and selectively trigger apoptosis in senescent cells (a 'senolytic'). Entirely experimental; no human trials.
Interferes with FOXO4 binding to p53 in senescent cells, releasing p53 to induce targeted apoptosis — demonstrated in mouse models of aging.
Single influential 2017 mouse study (Baar et al., Cell) plus preclinical follow-ups. No human safety or efficacy data.
Typical Dose
No established human dose
Frequency
Varies
Route
SubQ
Notes
Purely preclinical; dosing is extrapolated from rodent studies.
Aggregated from 11 lab-verified Certificates of Analysis uploaded directly by labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
11
Verified labs
0
Avg purity
99.79%
±0.16%
Endotoxin tested
36%
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs